Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives

Disseminate Cutaneous Vasculitis Associated with Durvalumab Treatment—Case Report, Mini-Review on Cutaneous Side Effects of Immune Checkpoint Inhibitor Therapies with Machine Learning Perspectives

Durvalumab is an IgG1 monoclonal antibody that has efficacy in many advanced-stage cancers, especially in small-cell lung cancer. The efficacy of durvalumab can be enhanced by chemotherapy. Cutaneous side effects due to treatment with durvalumab are usually self-limiting and easily manageable. We pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Gyula Laszlo Fekete, Laszlo Barna Iantovics, Júlia Edit Fekete, Laszlo Fekete
Format: Article
Language:English
Published: MDPI AG 2024-08-01
Series:Life
Subjects:
small-cell lung cancer
cancer
immunotherapy
durvalumab
vasculitis
cutaneous side effect
Online Access:https://www.mdpi.com/2075-1729/14/9/1062
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items